Peroxisome proliferator-activated receptor δ (PPARδ), a novel target site for drug discovery in metabolic syndrome
- 29 March 2006
- journal article
- review article
- Published by Elsevier in Pharmacological Research
- Vol. 53 (6) , 501-507
- https://doi.org/10.1016/j.phrs.2006.03.019
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- The metabolic syndromeThe Lancet, 2005
- ThiazolidinedionesNew England Journal of Medicine, 2004
- PPARs and the complex journey to obesityNature Medicine, 2004
- Association of the Metabolic Syndrome With History of Myocardial Infarction and Stroke in the Third National Health and Nutrition Examination SurveyCirculation, 2004
- PPARδ is a very low-density lipoprotein sensor in macrophagesProceedings of the National Academy of Sciences, 2003
- Prevalence of the Metabolic Syndrome Among US AdultsJAMA, 2002
- Rat PPARs: Quantitative Analysis in Adult Rat Tissues and Regulation in Fasting and RefeedingEndocrinology, 2001
- Growth, Adipose, Brain, and Skin Alterations Resulting from Targeted Disruption of the Mouse Peroxisome Proliferator-Activated Receptor β(δ)Molecular and Cellular Biology, 2000
- A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: The PPARα-null mouse as a model of fatty acid oxidation disordersProceedings of the National Academy of Sciences, 1999
- Peroxisome proliferator–activated receptor α mediates the adaptive response to fastingJournal of Clinical Investigation, 1999